<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636489</url>
  </required_header>
  <id_info>
    <org_study_id>2020HBβG-D</org_study_id>
    <nct_id>NCT04636489</nct_id>
  </id_info>
  <brief_title>Effect of Prebiotics on Blood Glucose Management</brief_title>
  <official_title>An Interventional Study for the Effects of Highland Barley β-glucan on the Management of Glucose Metabolism and Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This survey is designed to investigate the effect of highland barley β-glucan supplementation&#xD;
      on the regulatory of blood glucose, gut microbiota and cardiovascular risk fators in subjects&#xD;
      with hyperglycemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Highland barley β-glucan belongs to the group of prebiotics and has been found to be&#xD;
      associated with multiple health benefits. However, its protective role in subjects with&#xD;
      hyperglycemia are remain unclear. This study aims to examine the effect of 8-week prebiotics&#xD;
      supplementation on glucose management in subjects with hyperglycemia. By understanding the&#xD;
      mechanism by which prebiotics exert the beneficial effects, we can better control the rising&#xD;
      prevalence of hyperglycemia, which is a major risk factor for cardiovascular diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo-controlled, randomized clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, investigators and care providers at the scene are all blinded to the allocation of treatment group. Data collected will be analyzed by another investigator who is blinded to the study design.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>fasting venous plasma glucose</measure>
    <time_frame>baseline and after 8-week intervention</time_frame>
    <description>changes of fasting venous plasma glucose levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma glucose 2 h after an oral glucose load</measure>
    <time_frame>baseline and after 8-week intervention</time_frame>
    <description>changes of plasma glucose levels 2 h after an oral glucose load</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glycosylated hemoglobin</measure>
    <time_frame>baseline and after 8-week intervention</time_frame>
    <description>changes of glycosylated hemoglobin levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gut microbiota</measure>
    <time_frame>baseline and after 8-week intervention</time_frame>
    <description>changes of gut microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microbial metabolites</measure>
    <time_frame>baseline and after 8-week intervention</time_frame>
    <description>changes of microbial metabolites by untargeted metabolomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matsuda index</measure>
    <time_frame>baseline and after 8-week intervention</time_frame>
    <description>changes of Matsuda index based on OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>flow-mediated dilation</measure>
    <time_frame>baseline and after 8-week intervention</time_frame>
    <description>changes of flow-mediated dilation by VICORDER Complete Vascular Laboratory</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Highland barley β-glucan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given oral liquids mainly containing highland barley β-glucan once daily for 8 weeks followed by comprehensive physical and clinical examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be given oral liquids mainly containing Corn starch once daily for 8 weeks followed by comprehensive physical and clinical examinations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Highland barley β-glucan dietary supplement</intervention_name>
    <description>100 mL oral liquid mainly containing highland barley β-glucan once daily for 8 weeks</description>
    <arm_group_label>Highland barley β-glucan group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo controls</intervention_name>
    <description>Placebo with a similar appearance and taste to highland barley β-glucan supplement</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 30-65 years old&#xD;
&#xD;
          2. Fasting venous plasma glucose ≥5.6mmol/L OR plasma glucose 2 h after an oral glucose&#xD;
             load ≥7.8mmol/L OR glycosylated hemoglobin ≥5.7% OR newly diagnosed diabetes without&#xD;
             hypoglycemic drugs using&#xD;
&#xD;
          3. BMI≥18 kg/ m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receiving or have been treated with hypoglycemic drugs or insulin.&#xD;
&#xD;
          2. Complications including cardiovascular and cerebrovascular diseases such as coronary&#xD;
             heart disease and stroke.&#xD;
&#xD;
          3. Severe liver or renal insufficiency (alanine aminotransferase, aspartate&#xD;
             aminotransferase or alkaline phosphatase is greater than 3 times the upper limit of&#xD;
             normal OR GFR&lt;30ml/min/1.73m2).&#xD;
&#xD;
          4. Autoimmune diseases or thyroid diseases.&#xD;
&#xD;
          5. Women who are pregnant, nursing, or prepare to give birth during the trail.&#xD;
&#xD;
          6. Malignant disease, infectious disease, inflammatory disease and advanced liver&#xD;
             disease.&#xD;
&#xD;
          7. Mental or intellectual abnormalities, unable to sign informed consent.&#xD;
&#xD;
          8. Complications including chronic gastrointestinal disease; or suffered from acute&#xD;
             gastrointestinal diseases within 1 months before screening visit.&#xD;
&#xD;
          9. Received antibiotics, probiotics within 3 months before screening visit or throughout&#xD;
             the trail.&#xD;
&#xD;
         10. Major operations were performed within six months of screening visit, or will be made&#xD;
             during the trial.&#xD;
&#xD;
         11. Alcohol abuse (alcohol intake&gt;60g/d for male and alcohol intake&gt;40g/d for female)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Xia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Xia, PhD</last_name>
    <phone>+86 20 87332433</phone>
    <email>xiamin@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Xia, PhD</last_name>
      <phone>+86-2087332433</phone>
      <email>xiamin@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Min Xia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hyperglycemia</keyword>
  <keyword>Prebiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

